Glial cell line-derived neurotrophic factor: A novel therapeutic approach to treat motor dysfunction in Parkinson's disease

Experimental Neurology

Volumn 144, Issue 1, 1997, Pages 29-34

  Lapchak, Paul A ^a   Gash, Don M ^b   Jiao, Shoushu ^a   Miller, Paul J ^a   Hilt, Dana ^c  

^a Department of Neuroscience MC 5 1 C ^*  (United States)

^b UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^c AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; OXIDOPAMINE; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INJURY; DOPAMINERGIC SYSTEM; HUMAN; IMMUNOHISTOCHEMISTRY; LOCOMOTION; MONKEY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT;

EID: 0031104816     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.1996.6384     Document Type: Article

References (20)

1. 1. BOWENKAMP, K. E., A. F. HOFFMAN, G. A. GERHARDT, M. A. HENRY, P. T. BIDDLE, B. J. HOFFER, AND A. C. E. GRANHOLM. 1995. Glial cell line-derived neurotrophic factor supports survival of injured midbrain dopaminergic neurons. J. Comp. Neurol. 355: 479-489.
2. 2. BOWENKAMP, K. E., D. DAVID, P. A. LAPCHAK, M. A. HENRY, A. C. GRANHOLM, B. J. HOFFER, AND T. J. MAHALIK. 1996. 6-Hydroxydopamine induces the loss of the dopaminergic phenotype in SN neurons of the rat - a possible mechanism for restoration of the nigrostriatal circuit mediated by glial cell line derived neurotrophic factor. Exp. Brain Res. 111: 1-7.
3. 3. GASH, D. M., Z. ZHANG, W. A. CASS, A. OVADIA, L. SIMMERMAN, D. RUSSELL, D. MARTIN, F. C. COLLINS, B. J. HOFFER, AND G. A. GERHARDT. 1995. Morphological and functional effects of intranigrally administered GDNF in normal rhesus monkeys. J. Comp. Neurol. 363: 345-358.
4. 4. GASH, D. M., Z. ZHANG, A. OVADIA, W. A. CASS, A. YI, L. SIMMERMAN, D. RUSSELL, D. MARTIN, P. A. LAPCHAK, F. C. COLLINS, B. J. HOFFER, AND G. A. GERHARDT. 1996. Functional recovery in GDNF-treated Parkinsonian monkeys. Nature 380: 252-255.
5. 5. HOFFER, B. J., A. HOFFMAN, AND K. BOWENKAMP. 1994. Glial cell derived neurotrophic factor reversed toxin-induced injury to midbrain dopaminergic neurons in vivo. Neurosci. Lett. 182: 107-111.
6. 6. HOU, J. G. G., L. F. H. LIN, AND C. MYTILINEOU. 1996. Glial cell line-derived neurotrophic factor exerts neurotrophic effects on dopaminergic neurons in vitro and promotes their survival and regrowth after damage by 1-methyl-4-phenylpyridinium. J. Neurochem. 66: 74-82.
7. 7. HORNYKIEWICZ, O., S. J. FISH. 1986. Biochemical pathophysiology in Parkinson's disease. Adv. Neurol. 45:19-34.
8. 8. HUDSON, J., A. C. GRANHOLM, G. A. GERHARDT, M. A. HENRY, A. HOFFMAN, P. BIDDLE, N. S. LEELA, L. MACKERLOVA, J. D. LILE, F. COLLINS, AND B. J. HOFFER. 1995. Glial cell line-derived neurotrophic factor augments midbrain dopaminergic circuits in vivo. Brain Res. Bull. 36: 425-432.
9. 9. LIN, L-F., D. H. DOHERTY, J. D. LILE, S. BEKTESH, AND F. COLLINS. 1993. GDNF: A glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260: 1130-1132.
10. 10. LAPCHAK, P. A., S. S. JIAO, P. J. MILLER, L. R. WILLIAMS, V. CUMMINS, G. INOUYE, C. R. MATHESON, AND Q. YAN. 1996. Pharmacological characterization of glial cell line-derived neurotrophic factor: Implications for GDNF as a therapeutic molecule to treat neurodegenerative diseases. Cell Tissue Res. 286: 179-189.
11. 11. LAPCHAK, P. A., D. M. ARAUJO, D. M. GASH, D. HILT, B. J. HOFFER, AND F COLLINS. 1997. Glial cell line-derived neurotrophic factor (GDNF): Pharmacological activities and application to the treatment of Parkinson's disease. Exp. Neurol. (in press).
12. 12. LAPCHAK, P. A., F. COLLINS, D. GASH, B. HOFFER, G. GERHARDT, S. JIAO, P. J. MILLER, A. OVADIA, AND Z. ZHANG. 1996. Distribution of 125I-GDNF in the rat and primate CNS following an ICV injection: Correlation with the behavioral and pharmacological activities of ICV administered GDNF in Parkinson's disease models. Am. Soc. Neural. Transpl. P 52.
13. 13. LAPCHAK, P. A., P. J. MILLER, F. COLLINS AND S. S. JIAO. 1997. Glial cell line - derived neurotrophic factor attenuates behavioral deficits and regulates nigrostriatal dopaminergic and peptidergic markers in 6 hydroxy-dopamine lesioned adult rats: Comparison of intraventricular and intranigral delivery. Neuroscience, in press.
14. 14. LEENDERS, K. L., E. P. SALMON, P. TYRRELL, D. PERANI, D. J. BROOKS, H. SAGER, T. JONES, D. MARSDEN, AND R. S. J. FRANCHOWIAK. 1993. The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteers and in patients with Parkinson's disease. Arch. Neurol. 47: 1290-1298.
15. 3H]GBR 12935 binding to dopamine uptake sites: subcellular localization and reduction in Parkinson's disease and progressive supranuclear palsy. Eur. J. Pharmacol. 156: 331-340.
16. 16. MARSDEN, C. D., AND J. D. PARKES. 1976. 'On-Off' effects in patients with Parkinson's disease. Lancet 1: 292-296.
17. 17. MARSDEN, C. D., J. D. PARKES, AND N. QUINN. 1982. Fluctuations of disability in Parkinson's Disease - Clinical aspects. Pages 96-122, in C. D. Marsden and S. Fahn, Eds., Movement Disorders. Butterworths, London.
18. 18. SAUER, H., C. ROSENBLAD, AND A. BJORKLUND. 1995. Glial cell line-derived neurotrophic factor but not transforming growth factor B3 prevents delayed degeneration of nigral neurons following striatal 6-hydroxydopamine lesions. Proc. Natl. Acad. Sci. USA 92: 8935-8939.
19. 19. TOMAC, A., J. WIDENFALK, L. F. H. LIN, T. KOHNO, T. EBENDAL, B. J. HOFFER, AND L. OLSON. 1995. Retrograde axonal transport of GDNF in the adult nigrostriatal system suggests a trophic role in the adult. Proc. Natl. Acad. Sci. USA 92: 8274-8278.
20. 20. TORACK, R. M., AND J. C. MORRIS. 1992. Tyrosine hydroxylase-like (TH) immunoreactivity in Parkinson's disease and Alzheimer's disease. J. Neural Transm. 4: 165-171.